LLY · News · 20260917N

Regulatory Risk - Retatrutide Black Market

ELI LILLY & Co · 2026-09-17 · Importance 31 · Surprise 42

A CBS News investigation reported that companies are marketing and selling Eli Lilly’s experimental retatrutide online to U.S. consumers. Retatrutide remains in clinical trials and has not received regulatory approval for sale. Unapproved online distribution creates regulatory, compliance, patient-safety, and potential reputational risks for Lilly ahead of any future launch.

Key facts